The expert panel reached consensus in considering antihypertensive drugs (beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptors antagonists (ARBs), and dihydropyridine calcium channel blockers (CCBs)) as moderate-risk medication classes as they considered the risk of falls to be patient-specific (only for people who experience orthostatic hypotension), as well as dose and time-dependent. This evidence concerns the gene ACE and hypotensive disorder.